In the context of IL-15 immunotherapy, pharmacological targeting of STAT3 may thus be preferably only some time following the localization and priming-enhanced adaption of NK cells to hypoxic sites such as the tumor microenvironment. The gene discussed is STAT3; the disease is neoplasm.